Article
Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
World journal of gastroenterology - 28 Nov 2019
Yang Ying, Wu Feng-Ping, Wang Wen-Jun, Shi Juan-Juan, Li Ya-Ping, Zhang Xin, Dang Shuang-Suo
Abstract excerpt
BACKGROUND: Regimens involving direct-acting antiviral agents (DAAs) are recommended for the treatment of infection with hepatitis C virus (HCV) genotypes 1, 2 and 3. But real-world data is still not enough, especially in Asia. AIM: To investigate the efficacy and safety of DAA-based regimens in a real-life setting in China. METHODS: This study included 366 patients infected with HCV genotypes 1, 2 and 3, with or...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.